AAAAAA

   
Results: 1-8 |
Results: 8
THE EFFECT OF INTRAVENOUS ADMINISTRATION OF A CHIMERIC ANTI-IGE ANTIBODY ON SERUM IGE LEVELS IN ATOPIC SUBJECTS - EFFICACY, SAFETY, AND PHARMACOKINETICS
Authors: CORNE J DJUKANOVIC R THOMAS L WARNER J BOTTA L GRANDORDY B GYGAX D HEUSSER C PATALANO F RICHARDSON W KILCHHERR E STAEHELIN T DAVIS F GORDON W SUN L LIOU R WANG G CHANG TW HOLGATE S
Citation: J. Corne et al., THE EFFECT OF INTRAVENOUS ADMINISTRATION OF A CHIMERIC ANTI-IGE ANTIBODY ON SERUM IGE LEVELS IN ATOPIC SUBJECTS - EFFICACY, SAFETY, AND PHARMACOKINETICS, The Journal of clinical investigation, 99(5), 1997, pp. 879-887
EFFICACY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF CGP-51901, AN ANTIIMMUNOGLOBULIN-E CHIMERIC MONOCLONAL-ANTIBODY, IN PATIENTS WITH SEASONAL ALLERGIC RHINITIS
Authors: RACINEPOON A BOTTA L CHANG TW DAVIS FM GYGAX D LIOU RS ROHANE P STAEHELIN T VANSTEIJN AMP FRANK W
Citation: A. Racinepoon et al., EFFICACY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF CGP-51901, AN ANTIIMMUNOGLOBULIN-E CHIMERIC MONOCLONAL-ANTIBODY, IN PATIENTS WITH SEASONAL ALLERGIC RHINITIS, Clinical pharmacology and therapeutics, 62(6), 1997, pp. 675-690
IMMUNOASSAYS IN MONITORING BIOTECHNOLOGICAL DRUGS
Authors: GYGAX D BOTTA L EHRAT M GRAF P LEFEVRE G OROSZLAN P PFISTER C
Citation: D. Gygax et al., IMMUNOASSAYS IN MONITORING BIOTECHNOLOGICAL DRUGS, Therapeutic drug monitoring, 18(4), 1996, pp. 405-409
DEVELOPMENT, APPLICATION AND COMPARISON OF AN ENZYME-IMMUNOASSAY AND A HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY METHOD FOR THE DETERMINATION OF THE AROMATASE INHIBITOR CGS-20-267 IN BIOLOGICAL-FLUIDS
Authors: PFISTER CU DUVAL M GODBILLON J GOSSET G GYGAX D MARFIL F SIOUFI A WINKLER B
Citation: Cu. Pfister et al., DEVELOPMENT, APPLICATION AND COMPARISON OF AN ENZYME-IMMUNOASSAY AND A HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY METHOD FOR THE DETERMINATION OF THE AROMATASE INHIBITOR CGS-20-267 IN BIOLOGICAL-FLUIDS, Journal of pharmaceutical sciences, 83(4), 1994, pp. 520-524
PHARMACOKINETICS AND IMMUNOMODULATORY EFFECTS ON MONOCYTES DURING PROLONGED THERAPY WITH LIPOSOMAL MURAMYLTRIPEPTIDE
Authors: LANDMANN R OBRIST R DENZ H LUDWIG C FROST H WESP M RORDORF C TOWBIN H GYGAX D TARCSAY L OBRECHT JP
Citation: R. Landmann et al., PHARMACOKINETICS AND IMMUNOMODULATORY EFFECTS ON MONOCYTES DURING PROLONGED THERAPY WITH LIPOSOMAL MURAMYLTRIPEPTIDE, Biotherapy, 7(1), 1993, pp. 1-12
PHARMACOKINETICS OF AN HIV-1 GP120-SPECIFIC CHIMERIC ANTIBODY IN PATIENTS WITH HIV-1 DISEASE
Authors: SCHUPBACH J GUNTHARD H FUNG MSC LIOU RS BOTTA L GOWLAND P GORDON W GYGAX D CHANG NT CHANG TW LUTHY R BRAUN DG
Citation: J. Schupbach et al., PHARMACOKINETICS OF AN HIV-1 GP120-SPECIFIC CHIMERIC ANTIBODY IN PATIENTS WITH HIV-1 DISEASE, Biotherapy, 6(3), 1993, pp. 205-215
OPTIMIZATION OF A PROCESS FOR THE PRODUCTION OF (R)-2-HYDROXY-PHENYLBUTYRIC ACID - AN INTERMEDIATE FOR INHIBITORS OF ANGIOTENSIN-CONVERTINGENZYME (VOL 24, PG 315, 1992)
Authors: SCHMIDT E GHISALBA O GYGAX D SEDELMEIER G
Citation: E. Schmidt et al., OPTIMIZATION OF A PROCESS FOR THE PRODUCTION OF (R)-2-HYDROXY-PHENYLBUTYRIC ACID - AN INTERMEDIATE FOR INHIBITORS OF ANGIOTENSIN-CONVERTINGENZYME (VOL 24, PG 315, 1992), Journal of biotechnology, 31(2), 1993, pp. 233-233
COMPARATIVE PHARMACOKINETICS OF FREE MURAMYL TRIPEPTIDE PHOSPHATIDYL ETHANOLAMINE (MTP-PE) AND LIPOSOMAL MTP-PE
Authors: GAY B CARDOT JM SCHNELL C VANHOOGEVEST P GYGAX D
Citation: B. Gay et al., COMPARATIVE PHARMACOKINETICS OF FREE MURAMYL TRIPEPTIDE PHOSPHATIDYL ETHANOLAMINE (MTP-PE) AND LIPOSOMAL MTP-PE, Journal of pharmaceutical sciences, 82(10), 1993, pp. 997-1001
Risultati: 1-8 |